Regarding the FY2026 Medical Fee Revision (Effective April 2026) – mhlw.go.jp

Key News Points

This is information from the Ministry of Health, Labour and Welfare regarding the medical fee revision for FY2026 (effective from April 2026). This revision may impact the management and business succession strategies of medical institutions. Specifically, points raised include the need for mid-to-long-term plans considering the revision cycle, benefiting from economies of scale through group participation, and utilizing tax advantages by transitioning to specific medical corporations or social medical corporations.

M&A Medical Editorial Department’s Perspective

The FY2026 medical fee revision has once again highlighted the urgent need for management and succession strategies in medical institutions. In particular, viewing the revision cycle from a mid-to-long-term perspective, maintaining facility standards through group participation, dispersing the burden of capital investment, and considering tax schemes with a view to transitioning to specific medical corporations or social medical corporations are concrete steps for business continuity and development, not just cost reduction. For example, schemes where regional medical collaboration promotion corporations contribute to the realization of regional medical plans while utilizing tax benefits can be a strong option for business integration and reorganization through M&A. This revision presents a crucial moment to compare one’s own institution’s current status with its future vision and accelerate considerations for business succession and M&A.

Points Indicated by This News

• The FY2026 revision will accelerate the development of mid-to-long-term plans for the management and succession strategies of medical institutions.
• Group participation serves as a means to achieve economies of scale from the perspectives of maintaining facility standards and dispersing capital investment burdens.
• Transitioning to specific medical corporations or social medical corporations can be an important option for utilizing tax advantages and ensuring business continuity.
• Coordination with regional medical plans and collaboration with regional medical collaboration promotion corporations may also be key to responding to the revision.

Practical Questions Arising from This News

• Which medical specialties or services are particularly vulnerable to the impact of this medical fee revision?
• What are the specific advantages and disadvantages when considering group participation or changes in corporate status?
• What business succession or M&A scheme is optimal, considering the size of our institution and regional characteristics?

If You Feel “Should I Consult Too?”

Medical institution managers and successors who feel anxious about their institution’s revenue structure and future management strategy in light of the FY2026 medical fee revision should consider consulting with experts. In particular, professional knowledge from M&A intermediaries, tax accountants, and other specialists is indispensable for specifically grasping the impact of the revision and considering options such as group participation or changes in corporate status. Early consultation leads to more favorable terms for business succession and the establishment of a sustainable management system.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are handled with strict confidentiality. Free consultation here